Q1 2024 Earnings Summary
- Strong growth and positive outlook in Thermo Fisher's clinical research business, even after accounting for COVID headwinds, indicating robust underlying demand and excellent execution. Marc Casper stated that the business "just grew through" COVID headwinds and delivered "really an excellent start and excellent execution to deliver strong growth in the quarter."
- Positive developments in the biotech funding environment and China's stimulus program support Thermo Fisher's expectation of a modest pickup in economic activity as the year progresses, which bodes well for growth prospects. Marc Casper mentioned that "continued improvements in the biotech funding environment and the stimulus program that was announced by China" are positive signs, and that "those are good facts to support the modest step-up."
- Effective cost management and productivity improvements in the Life Sciences Solutions segment led to significant margin expansion, demonstrating strong operational execution. Stephen Williamson highlighted the "really good margin profile" and that the team has "done a great job" of managing costs given lower volumes.
- Declining revenues in the Life Sciences segment due to lower activity in the bioproduction business, with organic growth decreasing by 12% compared to the prior year quarter.
- The runoff of vaccines and therapies revenue is expected to pose a significant headwind, impacting overall revenue by $1.3 to $1.4 billion in 2024.
- Uncertainty about the timing and magnitude of improvements in key markets like China, with the company relying on modest pickup assumptions that may not materialize as expected.
-
Bioprocessing Destocking
Q: How did bioprocessing perform, and is destocking easing?
A: Bioproduction performed in line with expectations; organic growth declined due to strong comparisons, but orders have shown good sequential growth for two quarters, improving the book-to-bill ratio. Destocking is becoming more predictable. -
China Stimulus Impact
Q: When will China stimulus benefit revenues?
A: The China stimulus is a multiyear program; proposals are already with customers, but no orders yet. Expect orders later this year and some revenue late in the year, though significant benefits may be seen in 2025. The stimulus boosts confidence and signals China's efforts to grow the economy. -
Market Outlook
Q: What is the outlook for the rest of the year?
A: Market conditions played out as expected in Q1. Anticipate a modest pickup in economic activity as the year progresses, supported by improvements in biotech funding and the China stimulus. This sets up for stronger market conditions entering 2025. -
Pharma Services Opportunities
Q: Impact of Catalent's acquisition on pharma services?
A: With a competitor being acquired, capacity constraints in the CDMO space bode well for Thermo Fisher as the market leader. High activity levels and customer dialogues are leading to new business wins in pharma services. -
Clinical Research Growth
Q: Did clinical research grow despite COVID headwinds?
A: Yes, the clinical research business grew through COVID headwinds, delivering strong growth in the quarter. Momentum bodes well for midterm growth of high single digits plus synergies. -
Analytical Instruments Performance
Q: How did Analytical Instruments perform, especially mass spec?
A: Analytical Instruments had a strong quarter despite tough comparisons. Electron microscopy performed well with a strong order book. Chromatography and mass spectrometry saw good uptake on new products, with high-end research applications doing well and less exposure to routine uses. -
Lab Products and Services
Q: Are CRO and CDMO businesses picking up?
A: The CRO business (formerly PPD) had excellent execution, with strong performance and a pipeline of activity picking up, encouraged by improved biotech funding. The CDMO business is also seeing positive market dynamics. -
Life Sciences Margins
Q: What's driving Life Science Solutions margins?
A: Strong margins are due to addressing the cost base given lower volumes from pandemic unwind and bioproduction aspects. The team has effectively managed costs. -
Geopolitical Risks
Q: Are customers worried about China retaliation over Biosecure Act?
A: It's not prudent to speculate. Thermo Fisher's role is to support customers globally and navigate regulations. No material impact is anticipated in the short term.